EU and US could reach trade deal this weekend - Reuters
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a biopharmaceutical company with a market capitalization of approximately $879 million, announced today the results from its 2025 annual meeting of stockholders held on June 10, 2025. The company’s stock has shown remarkable strength, delivering a 75% return over the past year. According to InvestingPro analysis, LENZ appears to be trading above its Fair Value. The meeting saw the election of directors and ratification of the company’s independent auditor.
A total of 17,983,676 shares were represented at the meeting, out of 27,544,520 shares outstanding as of the record date, April 14, 2025. The stockholders elected Kimberlee C. Drapkin, Zach Scheiner, Frederic Guerard, and James McCollum as directors. Drapkin and Scheiner will serve as Class III directors until the 2027 annual meeting, while Guerard and McCollum will serve as Class I directors until the 2028 annual meeting. InvestingPro data shows the company maintains a strong financial health score, with liquid assets significantly exceeding short-term obligations.
In the election, Drapkin received 12,390,015 votes in favor and 3,157,989 votes withheld, with 2,435,672 broker non-votes. Scheiner received 12,714,299 votes for and 2,833,705 withheld, with an equal number of broker non-votes. Guerard garnered 15,369,962 votes in favor and 178,042 withheld, also with 2,435,672 broker non-votes. McCollum received 15,397,013 votes for, 150,991 withheld, and the same number of broker non-votes.
Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 17,979,770 votes for, 2,698 against, and 1,208 abstentions.
The results of the annual meeting are based on the information provided in the company’s 8-K filing with the Securities and Exchange Commission. The company, headquartered in Solana Beach, California, operates under the biological products industry and is incorporated in Delaware. Analysts maintain a strong buy consensus on LENZ, with price targets ranging from $36 to $60. For deeper insights into LENZ’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, LENZ Therapeutics reported its financial results for the first quarter of 2025, highlighting a net loss per share of $0.53, despite maintaining a strong cash position of $194.1 million. The company is focusing on its presbyopia treatment, LNZ100, with an FDA target action date set for August 8, 2025. LENZ Therapeutics has also entered into an exclusive licensing agreement with Lotus Pharmaceutical (TADAWUL:2070) for the commercialization of LNZ100 in select Asian markets, potentially bringing in up to $125 million in payments. Citi analysts have maintained a Buy rating on LENZ Therapeutics, emphasizing the potential FDA approval of LNZ100 as a significant milestone. The company continues to expand its sales force, with over 40% of offers accepted by experienced professionals, as it prepares for the anticipated product launch. LENZ Therapeutics’ management expressed confidence in their commercial strategy and the uniqueness of their product. The partnership with Lotus is expected to leverage Lotus’s commercial infrastructure to distribute LNZ100 upon approval. These developments reflect LENZ Therapeutics’ strategic efforts to position itself for growth in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.